Microneedles for treatment of peanut allergy

微针治疗花生过敏 花生过敏是一种危及生命的疾病。大约1%的美国人口(约300万人)种植花生 过敏，而且没有FDA批准的治疗方法。严格避免，不吃花生是唯一的选择 可用于管理花生过敏，这对患者和他们的生活方式施加了严格的限制 家庭，并可能导致营养不足。这项提议的总体目标是开发一种涂层 以微针(MNS)为基础的皮肤免疫疗法(CIT)(MNS-CIT)治疗花生过敏。目前 花生的口服免疫疗法受到了广泛的关注。然而，口服免疫疗法的一个主要限制是 花生的口服剂量上升到数千毫克，这会产生不良反应。基于我们的 初步数据我们的假设是，包裹花生变应原的MNS可以安全地将花生变应原输送到 花生皮表层可产生持久的花生脱敏效果。我们的具体目标是：(I)发展私募股权- 包衣MN及其治疗花生过敏的近远期疗效评价(II) 描述花生MNS-CIT的作用机制，并(Iii)在新生猪模型上评估治疗效果 花生过敏症。 如果成功，这些研究将为开发一种新的、更安全的花生提供基础 变态反应免疫疗法治疗。

Microneedles for treatment of peanut allergy Peanut allergy is a life-threatening condition. About 1% of the US population (~3 million people) has peanut allergies, and there is no FDA-approved treatment. Strict avoidance, and a peanut-free diet is the only option available to manage peanut allergies, which imposes severe limitations on the lifestyle of the patient and their families, and can lead to nutritional deficiencies. The overall goal of this proposal is to develop a coated microneedles (MNs) based cutaneous immunotherapy (CIT) a.k.a (MNs-CIT) for peanut allergy. Presently peanut oral immunotherapy has received much attention. However, a major limitation of oral immunotherapy is that the peanut oral dose is escalated to thousands of milligrams, which causes adverse effects. Based on our preliminary data our hypothesis is that MNs coated with peanut allergen can safely deliver peanut allergen in to the superficial skin-layer to produce long-lasting peanut desensitization. Our specific aims are: (i) Develop PE- coated MNs and evaluate their short and long term therapeutic effectiveness in treating peanut allergy, (ii) Characterize the mechanism of peanut MNs-CIT, and (iii) Evaluate therapeutic efficacy in a neonatal pig model of peanut allergy. If successful, these studies will provide the foundation to support the development of a novel and safer peanut allergy immunotherapy treatment.